News | Antiplatelet and Anticoagulation Therapies | September 30, 2019

Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients

Results from the EVOLVE Short DAPT Study reported at TCT 2019

Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients

September 30, 2019 – Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not increase myocardial infarction (MI) or stent thrombosis (ST) in high bleeding risk (HBR) patients treated with a contemporary drug-eluting stent.

Findings were reported at the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Sept. 25-29 in San Francisco, sponsored by the Cardiovascular Research Foundation (CRF).

The study utilized a thin-strut platinum-chromium stent (Synergy) that elutes everolimus from an ultrathin abluminal layer of a bioabsorbable polymer. Drug release and polymer degradation are complete within fours months of implantation. These design elements may facilitate endothelialization and enable shorter duration DAPT than used in pivotal approval trials.

The study enrolled 2,009 HBR patients (age ≥75 years with bleeding risk outweighing benefit of DAPT greater than three months, chronic anticoagulation, major bleeding within 12 months, history of stroke, thrombocytopenia, or renal insufficiency/failure) at 110 sites around the world. Patients with acute MI or complex lesions were excluded. After undergoing PCI, patients were required to take DAPT (aspirin+P2Y12 inhibitor) for three months, except those on chronic anticoagulant in whom aspirin was optional. Event-free patients (stroke, MI, revascularization, ST) who discontinued the P2Y12 inhibitor at three months, but continued aspirin between three and 15 months, were included in the primary analysis.

Clinical follow-up at three months was 95.2 percent (n=1,912). Of those, 77.7 percent (n=1,487) were eligible to discontinue the P2Y12 inhibitor. The analysis population for the secondary endpoint of BARC 2,3 or 5 bleeding was 1,032 due to 455 patients being excluded because they were on anticoagulation.

One co-primary endpoint assessed death or myocardial infarction between three and 15-months post- procedure, compared for non-inferiority to a propensity-adjusted historical limus-eluting stent control group receiving 12-month DAPT. The event rate for patients who received three-month DAPT (n=1,454) was 5.6 percent vs. 5.7 percent in the historical control group receiving 12-month DAPT (n=1,493, non-inferiority p=0.0016). The second co-primary endpoint of ARC definite/probable ST in patients with three-month DAPT between three and 15 months was also met with an incidence of 0.3 percent compared to a 1 percent performance goal (non-inferiority p<0.0001). The secondary endpoint was the rate of BARC 2/3/5 bleeding in patients compared for superiority to the propensity-adjusted historical control. The rate of BARC 2/3/5 bleeding in patients receiving three-month DAPT (n=974) was 6.26 percent compared to 4.17 percent in the 12-month DAPT group (n=947) (2.10%; 95 percent CI -0.10-4.29; p=0.98).

“These data prospectively demonstrate a low rate of adverse events for patients who are at high risk for bleeding and who then stop DAPT at three months,” said lead investigator Ajay J. Kirtane, M.D., SM. Kirtane is associate professor of medicine, Columbia University Irving Medical Center, chief academic officer, Center for Interventional Vascular Therapy and director, cardiac catheterization laboratories, NewYork-Presbyterian/Columbia University Irving Medical Center. “This is critically important information because the required duration of DAPT following implantation of current-generation drug- eluting stent platforms was previously unknown. These data better inform physicians on how best to tailor the recommended duration of DAPT to the bleeding risk of the patients they treat.”

Watch the VIDEO: What Went Wrong With the Absorb Stent?, an interview with Kirtane at TCT 2017.

The EVOLVE Short DAPT study was funded by Boston Scientific Corp. Kirtane disclosed institutional funding to Columbia University and/or the Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips and ReCor Medical.

More late-breaking coverage from TCT 2019

For more information: www.crf.org/tct

Related Content

News | Antiplatelet and Anticoagulation Therapies
October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...
Home October 04, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet ...

Home April 28, 2021
Home
Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

Home March 22, 2021
Home
Videos | Antiplatelet and Anticoagulation Therapies

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

Home October 19, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies

Roxana Mehran, M.D., and Marco Valgimiggle, M.D., present the results of the Xience 90/28 trials that evaluated the use ...

Home October 19, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies

Gregg Stone, M.D., presents the results of a pooled analysis of randomized trials of bivalirudin virus heparin in acute ...

Home October 17, 2020
Home
Subscribe Now